For research use only. Not for therapeutic Use.
TBK1-IN-1 is a potent and selective TANK binding kinase 1 (TBK1) inhibitor with an IC50 value of 22.4 nM. TBK1-IN-1 inhibits TBK1 downstream target genes cxcl10 and ifnβ expression. TBK1-IN-1 has anticancer activity[1].
TBK1-IN-1 (compound 7l; 0.1 and 1 μM; 2 h) inhibitsTBK1 downstream target genes cxcl10 and ifnβ expression in THP1 and RAW264.7 cells induced by poly (I:C) and lipopolysaccharide, respectively[1].
TBK1-IN-1 (1-100 μM; 72 h) has moderate antiproliferative activities against A549 and LLC with IC50 values of 17.6 and 9.4 μM, respectively[1].
| Catalog Number | I042353 |
| Synonyms | N-[3-[2-[3-[(4-acetylpiperazin-1-yl)methyl]anilino]pyrrolo[2,3-d]pyrimidin-7-yl]propyl]cyclobutanecarboxamide |
| Molecular Formula | C27H35N7O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C27H35N7O2/c1-20(35)33-15-13-32(14-16-33)19-21-5-2-8-24(17-21)30-27-29-18-23-9-12-34(25(23)31-27)11-4-10-28-26(36)22-6-3-7-22/h2,5,8-9,12,17-18,22H,3-4,6-7,10-11,13-16,19H2,1H3,(H,28,36)(H,29,30,31) |
| InChIKey | QVADRMQCYNOPPE-UHFFFAOYSA-N |
| SMILES | CC(=O)N1CCN(CC1)CC2=CC(=CC=C2)NC3=NC=C4C=CN(C4=N3)CCCNC(=O)C5CCC5 |
| Reference | [1]. Vassilev LT, et, al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004 Feb 6;303(5659):844-8. |
